The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH -Mutant Gliomas
Open accessPublished version of a preprint
Abstract
Purpose: Isocitrate dehydrogenase (IDH) gene mutations occur in low-grade and high-grade gliomas. We sought to identify the genetic basis of malignant phenotype heterogeneity in IDH-mutant gliomas. Methods: We prospectively implanted tumor specimens from 20 consecutive IDH1-mutant glioma resections into mouse brains and genotyped all resection specimens using a CLIA-certified molecular panel. Gliomas with cancer driver mutations were tested for sensitivity to targeted inhibitors in vitro. Associations between genomic alterations and outcomes were analyzed in patients. Results: By 10 months, 8 of 20 IDH1-mutant gliomas developed intracerebral xenografts. All xenografts maintained mutant IDH1 and high levels of 2-hydroxyglutarate on serial transplantation. All xenograft-producing gliomas harbored “lineage-defining” mutations in CIC (oligodendroglioma) or TP53 (astrocytoma), and 6 of 8 additionally had activating mutations in PIK3CA or amplification of PDGFRA, MET, or N-MYC. Only IDH1 and CIC/TP53 mutations were detected in non–xenograft-forming gliomas (P = 0.0007). Targeted inhibition of the additional alterations decreased proliferation in vitro. Moreover, we detected alterations in known cancer driver genes in 13.4% of IDH-mutant glioma patients, including PIK3CA, KRAS, AKT, or PTEN mutation or PDGFRA, MET, or N-MYC amplification. IDH/CIC mutant tumors were associated with PIK3CA/KRAS mutations whereas IDH/TP53 tumors correlated with PDGFRA/MET amplification. Presence of driver alterations at progression was associated with shorter subsequent progression-free survival (median 9.0 vs. 36.1 months; P = 0.0011). Conclusion: A subset of IDH-mutant gliomas with mutations in driver oncogenes has a more malignant phenotype in patients. Identification of these alterations may provide an opportunity for use of targeted therapies in these patients. Clin Cancer Res; 20(11); 2898–909. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IDH1 mutations are early events in the development of glial cancer (Watanabe et al., 2009), raising the possibility that IDH mutations are important for tumor initiation, but accumulation of additional oncogenic mutations renders GBM tumors less dependent on constitutive expression of mutant IDH for tumor proliferation and progression (Johnson et al., 2014; Wakimoto et al., 2014).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Wakimoto et al., 2014
In the citing paper
“Network analysis of the several driver mutation genes, including KMT2D138, PIK3CA139, PTEN140, and IDH1141, that regulate signaling and metabolic pathways in KRAS-driven cancers, connects them to oncogenic RAS (Fig 4c).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [140]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,890
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,888
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
The multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,858
Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362
Cited by
Sorted by citations
Items 101–189 of 189
Borodovsky, A., Meeker, A. K., Kirkness, E. F., Zhao, Q., Eberhart, C. G., Gallia, G. L., & Riggins, G. J. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1672-2 · Cited by 18
An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors
Verdura, S., Cuyàs, E., Lozano‐Sánchez, J., Bastidas-Velez, C., Llorach-Parés, L., Fernández‐Arroyo, S., Hernández‐Aguilera, A., Joven, J., Nonell‐Canals, A., Bosch‐Barrera, J., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy159 · Cited by 17
Tanaka, S., Luk, S. O., Kiyokawa, J., Onozato, M. L., Iafrate, A. J., Shah, K., Martuza, R. L., Rabkin, S. D., Batchelor, T. T., Cahill, D. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37437-2 · Cited by 15
Self-citationRomo, C. G., Palsgrove, D. N., Sivakumar, A., Elledge, C. R., Kleinberg, L. R., Chaichana, K. L., Gocke, C. D., Rodríguez, F. J., & Holdhoff, M. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0793-5 · Cited by 16
Juratli, T. A., Lautenschlaeger, T., Geiger, K. D., Pinzer, T., Krause, M., Schackert, G., & Krex, D. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1822-1 · Cited by 15
Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors
Kitagawa, Y., Kobayashi, A., Cahill, D. P., Wakimoto, H., & Tanaka, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189102 · Cited by 13
Self-citationIDH1- and IDH2-mutations in brain glial tumors - the new antioncogenic mechanism
Demyashkin, G. A., & Nikitin, P. V. (2018) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201811841134-139 · Cited by 13
Carney, S. V., Banerjee, K., Mujeeb, A., Zhu, B. J., Haase, S., Varela, M. L., Kadiyala, P., Tronrud, C. E., Zhu, Z., Mukherji, D., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1896 · Cited by 14
Self-citationTiburcio, P. D. B., Xiao, B., Berg, S., Asper, S., Lyne, S. B., Zhang, Y., Zhu, X., Yan, H., & Huang, L. E. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1800-0 · Cited by 12
RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells
Mukherjee, J., Pandita, A., Chatla, K., Johannessen, T.-C. A., Ohba, S., Tang, Y., Ore, C. L. D., Bjerkvig, R., & Pieper, R. O. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc7211 · Cited by 12
RetractedAvşar, T., Kose, T. B., Oksal, M. D., Turan, G., & Kılıç, T. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07750-1 · Cited by 11
Xue, W., Zhang, J., Tong, H., Xie, T., Chen, X., Zhou, B., Wu, P., Zhong, P., Du, X., Guo, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00711 · Cited by 11
TRIM25 promotes Capicua degradation independently of ERK in the absence of ATXN1L
Wong, D., Sogerer, L., Lee, S. S., Wong, V., Lum, A. M., Levine, A., Marra, M. A., & Yip, S. S. F. (2020) · BMC Biology · doi:10.1186/s12915-020-00895-0 · Cited by 11
Triptolide inhibits the progression of Glioblastoma U251 cells via targeting PROX1
Yuan, C., Liao, Y., Liao, S., Huang, M. N., Li, D., Wu, W., Quan, Y., Li, L., Yu, X., & Si, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1077640 · Cited by 9
Implications of molecular classifications in glioma surgery
Kalluri, A. L., Lee, J. H., Lucas, C. G., Rincón-Torroella, J., & Bettegowda, C. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04883-0 · Cited by 9
Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma
Liu, Z., Rao, M., Poiret, T., Nava, S., Meng, Q., von Landenberg, A., Bartek, J. J., Xie, S., Sinclair, G., Peredo, I. H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20303 · Cited by 9
Tiburcio, P. D. B., Xiao, B., Chai, Y., Asper, S., Tripp, S. R., Gillespie, D. L., Jensen, R. L., & Huang, E. L. (2018) · Oncotarget · doi:10.18632/oncotarget.26203 · Cited by 9
Oncogenic KRAS hotspot mutations are rare in IDH‐mutant gliomas
Schittenhelm, J., Krischker, N., Gepfner‐Tuma, I., Behling, F., Noell, S., Eckert, F., Biskup, S., & Tabatabai, G. (2019) · Brain Pathology · doi:10.1111/bpa.12709 · Cited by 9
Adapting the drivers to the road: a new strategy for cancer evolution?
Touat, M., Dhermain, F. G., André, F., & Sanson, M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv137 · Cited by 11
IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies
Bray, A., & Sahai, V. (2025) · Current Oncology · doi:10.3390/curroncol32010044 · Cited by 9
C-13 Hyperpolarized MR Spectroscopy for Metabolic Imaging of Brain Tumors
Viswanath, P., Li, Y., & Ronen, S. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_12 · Cited by 8
Miyake, Y., Fujii, K., Nakamaura, T., Ikegaya, N., Matsushita, Y., Gobayashi, Y., Iwashita, H., Udaka, N., Kumagai, J., Murata, H., et al. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa161 · Cited by 8
Self-citationDono, A., Alfaro-Munoz, K. D., Yan, Y., Lopez-Garcia, C. A., Soomro, Z., Williford, G. L., Takayasu, T., Robell, L., Majd, N., de Groot, J., et al. (2022) · Neurosurgery · doi:10.1227/neu.0000000000001875 · Cited by 9
Rosiak, K., Grot, D., & Rieske, P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239325 · Cited by 6
Yang, G., Yang, W., & Kiarasi, F. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70758 · Cited by 9
Tateishi, K., & Yamamoto, T. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84543 · Cited by 7
Self-citationGlioblastoma molecular and histological heterogeneity
Nikitin, P. V., Ryzhova, M. V., Aa, P., Galstyan, S. A., Kim, D. S., Panina, T. N., Shugay, S., Старовойтов, Д. В., Хохлова, Е. А., & Zubova, I. V. (2020) · CLINICAL AND EXPERIMENTAL MORPHOLOGY · doi:10.31088/cem2020.9.3.5-11 · Cited by 7
Coronary artery disease-associated immune gene RBP1 and its pan-cancer analysis
Wang, Y., Zhang, L., Chen, H., Yang, J., Cui, Y., & Wang, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1091950 · Cited by 6
Sharif, S. A. I., Harman, N., Hydock, D. S., & Olson, T. P. (2024) · World Academy of Sciences Journal · doi:10.3892/wasj.2024.256 · Cited by 6
Primary intraventricular tumors - Imaging characteristics, post-treatment changes and relapses
Chong, A. W.-L., McAdory, L. E., Low, D. C. Y., Lim, E. J., Leong, N. W. L., & Ho, C. L. (2021) · Clinical Imaging · doi:10.1016/j.clinimag.2021.10.008 · Cited by 5
Tateishi, K., Miyake, Y., Nakamura, T., Iwashita, H., Hayashi, T., Oshima, A., Honma, H., Hayashi, H., Sugino, K., Kato, M., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01683-x · Cited by 5
Self-citationAdvances in the treatment of IDH-mutant gliomas
Baek, C., Laurenge, A., & Touat, M. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001316 · Cited by 7
Qin, Y., Qi, Y., Zhang, X., Guan, Z., Han, W., & Peng, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052828 · Cited by 5
Spatial synaptic connectivity underlies oligodendroglioma evolution and recurrencePreprint
Raleigh, D. R., Mirchia, K., Oten, S., Picart, T., Nguyen, M., Ambati, V. S., Vasudevan, H. N., Young, J., Taylor, J. W., Krishna, S., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6299872/v1 · Cited by 5
Arakawa, Y., Saito, R., Kanemura, Y., Mishima, K., Koriyama, S., Narita, Y., Kumabe, T., Motomura, K., Sugiyama, K., Yamasaki, F., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf258 · Cited by 5
Epigenetic dysregulation in cancers by isocitrate dehydrogenase 2 (IDH2)
Nayarisseri, A., Bandaru, S., Khan, A., Sharma, K., Bhrdwaj, A., Kaur, M. P., Ghosh, D., Chopra, I., Panicker, A., Kumar, A., et al. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.12.012 · Cited by 4
T2/T2-FLAIR mismatch sign as a predictive biomarker for anaplastic astrocytoma genetic profile
Belyaev, A. Y., Usachev, D. Y., Pronin, I., Batalov, A. I., Afandiev, R. M., & Galstyan, S. A. (2021) · Medical Visualization · doi:10.24835/1607-0763-959 · Cited by 4
Chen, H.-W., Lin, M.-C., Wu, P., Chang, Y., Weng, S.-S., & Tsai, W. (2022) · The Chinese Journal of Physiology · doi:10.4103/cjp.cjp_97_21 · Cited by 4
Diversity of metabolic features and relevance to clinical subtypes of gliomas
Dasgupta, P., & Puduvalli, V. K. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.03.008 · Cited by 3
HR eye & MMR eye: one-day assessment of DNA repair-defective tumors eligible for targeted therapy
Saito, S., Kato, S., Arai, U., En, A., Tsunezumi, J., Mizushima, T., Tateishi, K., & Adachi, N. (2025) · Nature Communications · doi:10.1038/s41467-025-59462-2 · Cited by 4
Self-citationRETRACTED: Physical activity and glioblastoma: a paradigm shift in neuro-oncology therapy
Xie, L., & Wang, F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1638060 · Cited by 5
RetractedChi, A. S., Cahill, D. P., Larvie, M., & Louis, D. N. (2016) · New England Journal of Medicine · doi:10.1056/nejmcpc1610101 · Cited by 3
Self-citationExner, N. D., Valenzuela, J. A. C., Abou‐El‐Ardat, K., Miletić, H., Huszthy, P. C., Radehaus, P. M., Schröck, E., Bjerkvig, R., Kaderali, L., Klink, B., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26950 · Cited by 3
Central Nervous System: Progress of Today and a Preview of Tomorrow
Shih, H. A. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.10.035 · Cited by 3
Nikitin, P. V., Aa, P., Ryzhova, M. V., Shurkhay, V. A., Kulikov, E. E., Zhvansky, E. S., Popov, I. A., & Николаев, Е. Н. (2018) · Burdenko s Journal of Neurosurgery · doi:10.17116/neiro2018823112 · Cited by 3
MRE11 and UBR5 Co-Operate to Suppress RNF168-Mediated Fusion of Dysfunctional Telomeres
Tang, Y., Mukherjee, J., & Pieper, R. O. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.772233 · Cited by 3
Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1 -mutant gliomaPreprint
Kayabölen, A., Yilmaz, E., Şahin, G. N., Seker-Polat, F., Cingöz, A., Isik, B., Acar, S., Wakimoto, H., Cahill, D. P., Solaroğlu, İ., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.26.400234 · Cited by 5
Self-citationAutopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells
Hu, L., Lin, J., Sun, L., Berezuk, A., Tuttle, K. S., Zhu, X. Q., Seo, H., Dhe‐Paganon, S., Li, P., Sun, Y., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-025-02131-8 · Cited by 3
Self-citationProst, D. M., Nichelli, L., Rozenblum, L., Laurenge, A., Dehais, C., Mathon, B., Jacob, J., Drouiche, L., Escamilla-Ramírez, Á., Houillier, C., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0279 · Cited by 2
The Distribution and Significance of IDH Mutations in Gliomas
Tran, N. T. N. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.97380 · Cited by 2
Karakurt, S., Durmus, I. M., Erturk, S., Akalin, H. S., & Baş, K. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_13 · Cited by 2
HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy
Lee, J. Y., Park, J., & Hong, D. (2024) · Animal Cells and Systems · doi:10.1080/19768354.2024.2347538 · Cited by 2
Translational Research Platform for Malignant Central Nervous System Tumors
Tateishi, K. (2024) · Neurologia medico-chirurgica · doi:10.2176/jns-nmc.2024-0078 · Cited by 1
Self-citationQin, X., Chen, Z., Wu, L., & Ding, R. (2024) · Medicine · doi:10.1097/md.0000000000039316 · Cited by 2
Genomic Analysis in the Practice of Surgical Neuropathology: The Emory Experience
Neill, S. G., Saxe, D., Rossi, M. R., Schniederjan, M., & Brat, D. J. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0276-sai · Cited by 2
What's New in Grade II and Grade III Gliomas?
Wick, W., & Miller, J. J. (2018) · Seminars in Neurology · doi:10.1055/s-0037-1620275 · Cited by 2
The molecular history of IDH‐mutant astrocytomas without adjuvant treatment
Shi, Z., Li, K. K., Kwan, J. S. H., Chung, N. Y., Wong, S., Chu, A. W., Chen, H., Chan, D. T.-M., Mao, Y. Q., & Ng, H. (2024) · Brain Pathology · doi:10.1111/bpa.13300 · Cited by 1
Future Directions in the Treatment of Low-Grade Gliomas
Kinslow, C. J., & Mehta, M. P. (2025) · The Cancer Journal · doi:10.1097/ppo.0000000000000759 · Cited by 1
Nitrogen metabolism profiling reveals cell state-specific pyrimidine synthesis pathway choice
Savani, M. R., Li, B., Smith, B. C., Gu, W., Xiao, Y., Baquer, G., Shipman, T. E., Oken, S., Manoj, N., Zacharias, L. G., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01520-0 · Cited by 4
Fujimoto, K., Honda‐Kitahara, M., Hattori, N., Matsushita, Y., Hibiya, Y., Satomi, K., Matsunaga, H., Tsutsumi, S., Okamoto, A., Inoue, T., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-02989-5 · Cited by 1
Self-citationKitagawa, Y., Muzyka, L., Kobayashi, A., Wetzel, E., Nasser, A. M., Miller, J. J., Wakimoto, H., & Cahill, D. P. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag057 · Cited by 1
Self-citationUdutha, S., Batsios, G., Taglang, C., Gillespie, A. M., & Viswanath, P. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag063 · Cited by 1
Gliomas phenocopy an inborn error of metabolism to drive neuronal activity and tumor growth
Abdullah, K. G., Miki, K., Edgar, C. K., Wu, S. A., Xiao, Y., Huang, Y.-T., Drexler, R., Krishna, S., Puliyappadamba, V. T., Tay, L. W. R., et al. (2026) · Cell · doi:10.1016/j.cell.2026.08.037 · Cited by 2
ASCO 2023: new treatment options in CNS tumors
Pichler, J. (2023) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-023-00915-z · Cited by 1
The UTX Tumor Suppressor Directly Senses Oxygen to Control Chromatin and Cell FatePreprint
Chakraborty, A. A., Laukka, T., Myllykoski, M., Ringel, A. E., Booker, M. A., Tolstorukov, M. Y., Meng, Y. J., Meier, S., Jennings, R. B., Creech, A. L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/510479 · Cited by 1
Understanding and imaging PHGDH-driven intrinsic resistance to mutant IDH inhibition in gliomasPreprint
Taglang, C., Batsios, G., Gillespie, A. M., Phillips, J. J., Taylor, J. W., & Viswanath, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.30.673205 · Cited by 1
Molecular Therapy for Oligodendrogliomas
Miller, J. J., & Wen, P. Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813158-9.00031-1
Introduction to Heterogeneity in Statistical Genetics
Gordon, D., Finch, S. J., & Kim, W. (2020) · Statistics for biology and health · doi:10.1007/978-3-030-61121-7_1
Verheul, C., Ntafoulis, I., Kers, T. V., Hoogstrate, Y., Mastroberardino, P. G., Barnhoorn, S., Payán‐Gómez, C., Yen, R. T. C., Struys, E. A., Koolen, S. L. W., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.09.435131
Tateishi, K., & Yamamoto, T. (2021) · Japanese Journal of Neurosurgery · doi:10.7887/jcns.30.280
Self-citationKarakurt, S., Durmus, I. M., Erturk, S., Akalin, H. S., & Baş, K. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_13-1
An atlas of causal and mechanistic drivers of interpatient heterogeneity in gliomaPreprint
Turkarslan, S., He, Y.-Q., Hothi, P., Murie, C., Nicolas, A., Kannan, K. K., Park, J. H., Pan, M., Awawda, A., Cole, Z., et al. (2024) · medRxiv · doi:10.1101/2024.04.05.24305380
Focal cortical dysplasia type IIIb associated with a KRAS-mutant ganglioglioma
Repnikova, E. A., Zhang, L., Orr, B. A., Roberts, J. A., Zinkus, T. P., Gener, M., & Kats, A. (2024) · Cancer Genetics · doi:10.1016/j.cancergen.2024.07.004
Targeting IDH mutation: another milestone, but not the finish line
Jakola, A. S., & Rydén, I. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00491-7
Yoshii, Y., Hihara, F., Matsumoto, H., Igarashi, C., Tachibana, T., Shinada, M., Ohtake, M., Suzuki, H., Zhang, M.-R., Oshima, A., et al. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2025.111325
Self-citationWong, D. T. W., Sogerer, L., Lee, S. S., Wong, V., Lum, A., Levine, A. B., Marra, M. A., & Yip, S. (2020) · Figshare · doi:10.6084/m9.figshare.13161573
Wong, D. T. W., Sogerer, L., Lee, S. S., Wong, V., Lum, A., Levine, A. B., Marra, M. A., & Yip, S. (2020) · Figshare · doi:10.6084/m9.figshare.13161561
Tateishi, K., Miyake, Y., Nakamura, T., Iwashita, H., Hayashi, T., Oshima, A., Honma, H., Hayashi, H., Sugino, K., Kato, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26645494
Self-citationTateishi, K., Miyake, Y., Nakamura, T., Iwashita, H., Hayashi, T., Oshima, A., Honma, H., Hayashi, H., Sugino, K., Kato, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26645491
Self-citationWong, D. T. W., Sogerer, L., Lee, S. S., Wong, V., Lum, A., Levine, A. B., Marra, M. A., & Yip, S. (2020) · Figshare · doi:10.6084/m9.figshare.13161564
Makino, Y., Arakawa, Y., Yoshioka, E., Shofuda, T., Minamiguchi, S., Kawauchi, T., Tanji, M., Kanematsu, D., Nonaka, M., Okita, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16625380
Wong, D. T. W., Sogerer, L., Lee, S. S., Wong, V., Lum, A., Levine, A. B., Marra, M. A., & Yip, S. (2020) · Figshare · doi:10.6084/m9.figshare.13161576
Wong, D. T. W., Sogerer, L., Lee, S. S., Wong, V., Lum, A., Levine, A. B., Marra, M. A., & Yip, S. (2020) · Figshare · doi:10.6084/m9.figshare.13161558
Wong, D. T. W., Sogerer, L., Lee, S. S., Wong, V., Lum, A., Levine, A. B., Marra, M. A., & Yip, S. (2020) · Figshare · doi:10.6084/m9.figshare.13161537
Wong, D. T. W., Sogerer, L., Lee, S. S., Wong, V., Lum, A., Levine, A. B., Marra, M. A., & Yip, S. (2020) · Figshare · doi:10.6084/m9.figshare.13161570
Saito, S., Kato, S., Arai, U., Tateishi, K., & Adachi, N. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102858
Self-citationPRDM players in central nervous system cancers: State of the art and future perspectives
Zazzo, E. D., Donato, M. D., Rienzo, M., Casamassimi, A., Fiore, D., Proto, M. C., Gazzerro, P., & Abbondanza, C. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105293
Characterization of cellular heterogeneity in Diffuse Low Grade Glioma
Augustus, M. (2020) · theses.fr (ABES) · doi:10.70675/037c23a4z44ddz4bb7z999ezb0c178c35170
Autophagy inhibition sensitizes radiotherapy responses in high-grade mutant IDH1 glioma
Núñez, F. J., Banerjee, K., Mujeeb, A., Mauser, A., Tronrud, C. E., Zhu, Z., Raghuram, S., Sheth, M. R., Agudelo, J. A. P., Zelaya, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77320-7 · Cited by 1
Metadata
- Authors
- Wakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., Dias-Santagata, D., Ellisen, L. W., Borger, D. R., Fendt, S.-M., Vander Heiden, M. G., Batchelor, T. T., Iafrate, A. J., Cahill, D. P., & Chi, A. S.
- Affiliations
- Harvard University (US)
- Authors' Affiliations: 1Department of Neurosurgery; 2Division of Hematology/Oncology, Department of Neurology, Stephen E. and Catherine Pappas Center for Neuro-Oncology, 3Translational Research Laboratory; 4Department of Pathology; 5Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge; 6Translational Neuro-Oncology Laboratory; 7Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts; 8Vesalius Research Center, VIB and Department of Oncology, KU Leuven, Leuven, Belgium
- Corresponding author
- Cahill, Daniel P.
- Chi, Andrew S.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2014-05-29
- Volume
- 20
- Issue
- 11
- Pages
- 2898-2909
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC4070445
- OpenAlex
- W2137361994
- Cited by
- 190
- References
- 51
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 16 · 2023: 12 · 2022: 10 · 2021: 22 · 2020: 27 · 2019: 19 · 2018: 18 · 2017: 15 · 2016: 9 · 2015: 15 · 2014: 3
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- Wellcome Trust
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Cancer Institute (K24CA125440, P50CA165962)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- IDH-mutant glioma, IDH1 mutation, CIC mutation, TP53 mutation, PIK3CA mutation, KRAS mutation, PDGFRA amplification, MET amplification, MYCN amplification, 2-hydroxyglutarate, tumor xenografts, cancer driver mutations, targeted therapy, progression-free survival, oligodendroglioma, astrocytoma
- MeSH terms
- Animals, Brain Neoplasms, Cell Transformation, Neoplastic, Glioma, Humans, Isocitrate Dehydrogenase, Gas Chromatography-Mass Spectrometry, Mutation, Oncogenes, Phenotype, In Situ Hybridization, Fluorescence, Disease-Free Survival, Mice, Kaplan-Meier Estimate, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
